

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 3/22/04 Signature: Joanne Ryan
(Joanne Ryan)

Docket No.: CIBT-P01-058
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Lu et al.

Application No.: 09/499526

Confirmation No.: 1398

Filed: February 10, 2000

Art Unit: 1647

For: METHODS AND REAGENTS FOR
TREATING GLUCOSE METABOLIC
DISORDERS

Examiner: R. M. Deberry

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of a Final Office Action or Notice of Allowance, whichever occurred first, but on or before payment of the Issue Fee (37 CFR 1.97(d)). Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered.

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent,


publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. CIBT-P01-058.

Dated: 3/22/04

Respectfully submitted,

By 

Melissa S. Rones, Ph.D.

Registration No.: 54,408
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
				Application Number	09/499526
				Filing Date	February 10, 2000
				First Named Inventor	Kuanghui Lu
				Art Unit	1647
				Examiner Name	R. M. Deberry
Sheet	1	of	1	Attorney Docket Number	CIBT-P01-058

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
AA		5,980,945	11-09-1999	Ruiz	
AB		6,391,343	05-21-2002	Yen	
AC		6,558,708	05-06-2003	Lin	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number-Kind Code ⁵ (if known)			
					T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
CA		Chen, C., et al., "PYY and NPY: control of gastric motility via action on Y1 and Y2 receptors in the DVC", <i>Neurogastroenterol. Mot.</i> , 9: 109-116 (1997)			T ²
CB		Chen, M., et al., "Sensitive Radioimmunoassay for Measurement of Circulating Peptide YY", <i>Gastroenterology</i> , 87: 1332-8 (1984)			
CC		Dos Santos Medeiros, M., et al., "Processing and Metabolism of Peptide-YY: Pivotal Roles of Dipeptidylpeptidase-IV, Aminopeptidase-P, and Endopeptidase-24.11*", <i>Endocrinology</i> , 134: 2088-2094 (1994)			
CD		Eberlein, G., et al., "A New Molecular Form of PYY: Structural Characterization of Human PYY (3-36) and PYY (1-36)", <i>Peptides</i> , 10: 797-803 (1989)			
CE		Grandt, D., et al., "Novel Generation of Hormone Receptor Specificity By Amino Terminal Processing of Peptide YY", <i>Biochemical and Biophysical Research Communications</i> , 186: 3: 299-1306 (1992)			
CF		Grandt, D., et al, "Two Molecular Forms of Peptide YY (PYY) are Abundant In Human Blood: Characterization of a Radioimmunoassay Recognizing PYY 1-36 and PYY 3-36", <i>Regulatory Peptides</i> , 51: 151-159 (1994)			
CG		Leibowitz, S.F., et al, "Analysis of Neuropeptide Y-Induced Feeding: Dissociation of Y(1) and Y(2) Receptor Effects on Natural Meal Patterns", <i>Peptides</i> , 12: 1251-1260 (1991)			
CH		Morley, J., "An Approach to the Development of Drugs for Appetite Disorders", <i>Neuropsychobiology</i> , 21: 22-30 (1989)			
CI		Morley, J., et al., "An Investigation of Tolerance to the Actions of Leptogenic and Anorexigenic Drugs in Mice", <i>Life Sciences</i> , 41: 2157-2165 (1987)			
CJ		Okada, S., et al, "Peripherally Not Centrally Administered Peptide YY (PYY) Decreases High Fat Diet Intake", <i>Endocrinology</i> , Abstract 520B (1993)			
CK		Tatemoto, K., et al, "Isolation and Primary Structure of Human Peptide YY", <i>Biochemical and Biophysical Research Communication</i> 157:2: 713-717 (1988)			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Examiner Signature	Date Considered
--------------------	-----------------